Jason A Chesney
Overview
Explore the profile of Jason A Chesney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
562
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Engelbrecht E, Stamp B, Chew L, Sarkar O, Harter P, Waigel S, et al.
JCI Insight
. 2025 Mar;
PMID: 40048259
The sentinel lymph node (SLN) is the first lymph node encountered by a metastatic cancer cell and serves as a predictor of poor prognosis, as patients with clinically occult SLN...
2.
Lypova N, Dougherty S, Clem B, Feng J, Yin X, Zhang X, et al.
Cancer Metab
. 2024 Dec;
12(1):37.
PMID: 39696407
Background: The efficacy of tyrosine kinase inhibitors (TKIs) targeting the EGFR is limited due to the persistence of drug-tolerant cell populations, leading to therapy resistance. Non-genetic mechanisms, such as metabolic...
3.
Robert C, Gastman B, Gogas H, Rutkowski P, Long G, Chaney M, et al.
Eur J Cancer
. 2024 Jun;
207:114120.
PMID: 38870745
Background: Treatment options for immunotherapy-refractory melanoma are an unmet need. The MASTERKEY-115 phase II, open-label, multicenter trial evaluated talimogene laherparepvec (T-VEC) plus pembrolizumab in advanced melanoma that progressed on prior...
4.
Nguyen T, Schneider G, Kaliappan A, Buscaglia R, Brock G, Hall M, et al.
Curr Oncol
. 2023 Jul;
30(7):6079-6096.
PMID: 37504313
Melanoma is the fifth most common cancer in the United States and the deadliest of all skin cancers. Even with recent advancements in treatment, there is still a 13% two-year...
5.
Sarkar O, Donninger H, Al Rayyan N, Chew L, Stamp B, Zhang X, et al.
Sci Adv
. 2023 Jun;
9(26):eadg3736.
PMID: 37390211
Immune checkpoint inhibitor (ICI) therapy is effective against many cancers for a subset of patients; a large percentage of patients remain unresponsive to this therapy. One contributing factor to ICI...
6.
Chesney J, Puzanov I, Collichio F, Singh P, Milhem M, Glaspy J, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37142291
Talimogene laherparepvec (T-VEC) plus ipilimumab has demonstrated greater antitumor activity versus ipilimumab alone, without additional toxicity, in patients with advanced melanoma. Here, we report the 5-year outcomes from a randomized...
7.
8.
Chesney J, Ribas A, Long G, Kirkwood J, Dummer R, Puzanov I, et al.
J Clin Oncol
. 2022 Aug;
41(3):528-540.
PMID: 35998300
Purpose: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase...
9.
Miller H, Rai S, Yin X, Zhang X, Chesney J, van Berkel V, et al.
Metabolomics
. 2022 May;
18(5):31.
PMID: 35567637
Introduction: Metabolomics has emerged as a powerful method to provide insight into cancer progression, including separating patients into low- and high-risk groups for overall (OS) and progression-free survival (PFS). However,...
10.
Yaddanapudi K, Stamp B, Subrahmanyam P, Smolenkov A, Waigel S, Gosain R, et al.
Clin Cancer Res
. 2022 Jan;
28(10):2069-2081.
PMID: 35046061
Purpose: Improving our understanding of the immunologic response to cancer cells within the sentinel lymph nodes (SLN) of primary tumors is expected to identify new approaches to stimulate clinically meaningful...